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Abstract
Background: Improved detection methods for diagnosis of malignant pleural mesothelioma (MPM) are essential for early
and reliable detection as well as treatment. Since recent data point to abnormal levels of microRNAs (miRNAs) in tumors, we
hypothesized that a profile of deregulated miRNAs may be a marker of MPM and that the levels of specific miRNAs may be
used for monitoring its progress.
Methods and Results: miRNAs isolated from fresh-frozen biopsies of MPM patients were tested for the expression of 88
types of miRNA involved in cancerogenesis. Most of the tested miRNAs were downregulated in the malignant tissues
compared with the normal tissues. Of eight significantly downregulated, three miRNAs were assayed in cancerous tissue
and adjacent non-cancerous tissue sample pairs collected from 27 formalin-fixed, paraffin-embedded MPM tissues by
quantitative RT-PCR. Among the miRNAs tested, only miR-126 significantly remained downregulated in the malignant
tissues. Furthermore, the performance of the selected miR-126 as biomarker was evaluated in serum samples of asbestos-
exposed subjects and MPM patients and compared with controls. MiR-126 was not affected by asbestos exposure, whereas
it was found strongly associated with VEGF serum levels. Levels of miR-126 in serum, and its levels in patients’ serum in
association with a specific marker of MPM, SMRPs, correlate with subjects at high risk to develop MPM.
Conclusions and Significance: We propose miR-126, in association with SMRPs, as a marker for early detection of MPM. The
identification of tumor biomarkers used alone or, in particular, in combination could greatly facilitate the surveillance
procedure for cohorts of subjects exposed to asbestos.
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Introduction
Malignant pleural mesothelioma (MPM) is an aggressive tumor
with poor prognosis, mostly linked to asbestos exposure [1].
Although the inhalation of asbestos fibers is a well known risk
factor, the lack of clinical symptoms in the early stages of the
disease as well as the lack of useful diagnostic markers makes early
diagnosis very difficult [2]. Current challenge in the management
of MPM includes the identification of sensitive and specific
biomarkers that can be exploited to detect early neoplastic changes
preferentially in a non-invasive manner thus facilitating the
detection of MPM at an early stage, as well as for monitoring
the progress of patients with MPM and their response to the
treatments. A number of circulating tumour markers have been
evaluated, but their sensitivity is low [3,4]. Recently, soluble
mesothelin-related peptides (SMRPs) have been suggested as
promising biomarkers for MPM [5]. The level of SMRP of 1 nM
was recommended as the best cut-off value to distinguish MPM
patients from controls. However, this approach does not
discriminate asbestos-exposed individuals from healthy controls.
Thus, the levels of SMRPs in the blood have be proposed as a
biomarker suitable for the diagnosis of existing MPM but not to
identify high-risk subjects [6,7]; neither is it useful as a screening
tool.
MPM is characterized by a long latency period from the time of
asbestos exposure to clinical diagnosis, suggesting that multiple
somatic changes may be required for the tumorigenic conversion
of normal mesothelial cells [8]. In this long promotion/
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ment, aberrations and deletions as well as epigenetic changes have
been proposed to occur.
It is known that epigenetic mechanisms are involved in the
regulation of microRNAs (miRNAs) [9,10], a class of naturally
occurring small non-coding RNAs of 19–25 nucleotides in length.
About 700 miRNAs have been identified in humans, with each
miRNA affecting up to 200 target genes by blocking the
translation of individual proteins [11]. These molecules are
involved in the regulation of up to one-third of all human genes
by promoting the degradation of target messenger RNA.
Aberrant expression of miRNAs has been shown to contribute
to the pathogenesis of several human diseases [12–14] including
cancer [15–17], and may serve as a valuable diagnostic or
prognostic marker for a variety of pathologies. Therefore, the
identification of a specific miRNA profile may be utilized for better
identification of cancer types [18,19]. We hypothesize that a
profile of deregulated miRNAs may be used for the detection of
MPM and that the levels of expression of specific miRNA species
could help monitoring the disease development.
In this study, the miRNA profile associated with the
development of MPM was evaluated by quantitative reverse
transcriptase-polymerase chain reaction (qRT-PCR) analysis of
biopsies freshly collected from patients with MPM and from
healthy subjects used as controls. Certain deregulated miRNA
species were selected and subjected to further analysis in a larger
series of samples. Among the miRNAs analyzed, the miR-126 was
found to be significantly downexpressed in malignant tissues. Next,
we tested the applicability of the selected miR-126 as a circulating
biomarker for early detection of MPM and risk-disease prediction.
Thus, the miR-126 levels were evaluated in serum samples of
asbestos-exposed subjects, defined as high-risk population to
develop the disease, and MPM patients, correlated with the level
of the angiogenic factor VEGF and SMRPs, and compared with
healthy subjects. Our results indicate that the miR-126 expression,
in particular in combination with SMRPs, may be used as a
marker to help diagnose of the neoplastic disease and could greatly
facilitate the surveillance procedure for cohorts of subjects exposed
to asbestos.
Results
MiRNA expression profile distinguishes MPM from
normal mesothelium
To determine the miRNA species differently expressed in the
MPM tissue compared with the normal mesothelial tissue, we used a
customized miRNA PCR array with 88 human miRNAs that are
known to play a role in cancer. By comparing miRNAs from freshly
collected MPM biopsies with pooled miRNAs from normal controls,
a miRNA ‘signature’ was obtained. Most of the miRNAs were
downregulated in the malignant tissue compared to the healthy
control samples (Fig. 1). The most significantly downregulated
miRNA species were miR-335 (fold change 217.861.9, p,0.009),
miR-130a (fold change 29.363.3, p,0.047), miR193b (fold change
25.261.1, p,0.012), miR-30c (fold change 26.861.1, p,0.02),
miR-212 (fold change 210.761.9, p,0.018), miR-126 (fold change
Figure 1. Hierarchical cluster analysis of miRNAs. miRNA
expression of 10 MPM tissues is shown with respect to the pooled
miRNAs from 5 normal tissues. MiRNAs were considered differentially
expressed if their levels were increased or decreased by more than 2-
fold. Relative normalized expression for each miRNA is represented by
color intensity (green, downregulation; yellow, no change in expression;
red, increased expression; black, miRNA not detected).
doi:10.1371/journal.pone.0018232.g001
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andmiR-181c (fold change 214.362.4, p,0.046).Correlations were
found between the levels of individual miRNA species, while no
correlation was detected between miRNAs and the tumor stage (data
not shown).
Three miRNA species most consistently downregulated, with
fold change of .15, were selected for a larger-scale analysis using
the paraffin-embedded tissue sections. We therefore analyzed the
expression of miR-335, miR-126 and miR-32 in the pairs of the
cancerous and the adjacent non-malignant tissue. The ROC
curves were generated to analyze the diagnostic value of individual
miRNA. When the number of samples was increased, miR-335
lost its significance to discriminate the pathological tissue (MPM
group) from the normal, control tissue (NM group), accuracy to
42% (26–58%, p=0.312). Therefore, only miR-126, accuracy to
70% (54–85%, p=0.024), and, to a lower extent, miR-32,
accuracy to 65% (50–80%, p=0.050), were significantly down-
regulated in the MPM group compared to the NM group allowing
to discriminate between cancerous and non-malignant tissues
(Fig. 2).
The MPM group was then divided into two sub-groups
according to the stage of the disease. The MPM tumors staged
S-Ia, S-Ib, or S-II without lymph nodes and metastases
involvement were included in the S1 group, while the MPM
tumors staged S-III or S-IV with lymph nodes and metastases were
included in the S2 group. We then compared the expression of
miR-335, miR-126 and miR-32 in these two groups. Although
without reaching statistical significance, all miRNAs were more
downregulated in the advanced S2 group (Fig. 3).
Circulating miR-126 differentiates asbestos-exposed
subjects from MPM patients and healthy controls
Recently, the expression profile of circulating miRNAs in the
serum has been suggested as a potential biomarker for cancer
detection [22–24]. It is widely accepted that asbestos inhalation is
the predominant cause of MPM, with ,80% of cases associated
with documented asbestos exposure [1]. We hypothesized that the
levels of specific miRNAs in the blood may be used to diagnose
possible pathological changes associated with inhalation of
asbestos fibres.
MiR-126, the most important marker in our previous screening
(see above), was evaluated in a cohort of asbestos-exposed subjects
defined as high-risk subjects, in MPM patients and in healthy
controls.
MiR-126 was correlated with the serum levels of the angiogenic
factor VEGF and the SMRPs, a specific marker of MPM [5,6].
Multivariate logistic regression analysis was performed to estimate
the influence of independent factors on the level of miR-126.
Among the various factors, such as asbestos-related diseases
(fibrosis and pleural plaques), duration of asbestos exposure,
cumulative fibre doses and markers of the disease (VEGF and
SMRPs), only VEGF levels were found to strongly correlate with
miR-126 (R=0.659, p=0.02). As shown in Fig. 4A,B, MPM
patients showed higher serum VEGF and SMRP levels relative to
the asbestos-exposed subjects and controls. On the other hand,
miR-126 can significantly differentiate the high-risk individuals
from the healthy controls and cancer group (Fig. 4C). Using ROC
analysis, cut-off values of miR-126 were determined to discrim-
inate asbestos-exposed subjects from controls (DCT=23.5;
sensitivity 60% and specificity 74%) and from MPM patients
(DCT=24.5; sensitivity 73% and specificity 74%).
To evaluate whether a combination of individual markers
may increase the predictive value for early detection of MPM,
SMRP levels, that can distinguish MPM patients from asbestos-
exposed subjects and controls with a cut-off of 1 nM, have been
found to correlate with serum miR-126 (Fig. 4D). The
probability of the risk to develop the disease was higher with
decreasing expression of miR-126, when correlated with
increasing levels of SMRPs.
Discussion
The prognosis of MPM patients is dismal despite current
therapeutic modalities that include surgery, chemotherapy, and
radiation of the thoracic drainage site [2,25,26]. In the early stage,
surgery may offer a chance for prolonged survival, but patients
need to be carefully selected, since less then 10% of the patients
are eligible for this therapeutic option [27]. In advanced stages,
chemotherapy with novel antifolates combined with cisplatin offers
a rather small, albeit significant survival advantage [28]. Early and
accurate diagnosis is important for appropriate therapeutic
intervention, which may result in prolonged survival of MPM
patients or, in the ideal case, their complete recovery.
Focus has been on finding tumor markers that can be used in
association with radiography for MPM detection [29]. Several
rather promising approaches have been suggested. For example,
patients with MPM show increased serum levels of the MPM-
specific peptide mesothelin and related peptides [5,30,31]. We
have recently identified the combination of SMRPs and the level
of expression of the vascular endothelial growth factor (VEGF)
together with 8-hydroxy-29-deoxyguanosine (a marker of oxidative
stress) as a potential indicator of early and advanced MPM [6].
Although these reports are encouraging, we decided to explore a
relatively different avenue to MPM diagnosis, based on the use of
miRNA profiling.
Accumulating reports strongly indicate the potential diagnostic
applications of miRNA in human cancers, also suggesting their
possible use in therapeutic applications [19,32,33]. Therefore,
miRNA expression profiles can be utilized to discriminate normal
from malignant tissue, to identify the tissue origin in poorly
differentiated tumors, or to distinguish cancers of unknown origin
as well as their sub-types.
To identify a specific miRNA signature, we first analyzed
human miRNAs with a potential role in malignant tissue freshly
obtained from MPM patients, which was compared with
corresponding samples of normal human mesothelium. This
approach revealed differences in the expression profile of miRNAs
in MPM samples and in the controls. We found that most miRNA
species were expressed at lower levels in the MPM samples
compared to the controls (cf Fig. 1). This result is in agreement
with several studies that reported an overall downregulation of
miRNAs in tumors compared to the corresponding normal tissue
[34,35].
An miRNA profile was previously identified by analyzing 17
biopsies freshly collected from MM patients for 723 human and 76
viral miRNAs [36]. Twelve miRNAs were highly expressed,
whereas nine were found to be downregulated. More recently,
Busacca and colleagues [37] evaluated miRNA expression profile
in cultured mesothelioma cells. The significantly deregulated
miRNAs were then further assessed by qRT-PCR and subse-
quently analyzed in 24 MM specimens, representative of three
tumor histotypes (epithelioid, biphasic, and sarcomatoid). A
pattern of deregulated miRNAs was found in these samples.
Although well carried out, these two studies reported different
profiles of miRNA expression, suggesting that both the selection of
the samples and the applied methodological approaches could
have affected the results. Gee and colleagues have recently
suggested that miRNA analysis can be used to distinguish MM
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PLoS ONE | www.plosone.org 3 April 2011 | Volume 6 | Issue 4 | e18232Figure 2. Box plot and ROC curves of miR-335, miR-126 and miR-32 expression levels. Distribution of miR-335, miR-126 and miR-32
expression levels (DCT) in malignant pleural mesothelioma (MPM) and normal mesothelial (NM) tissue (left panels). The areas under the receiver
operating curves (AUC) were determined for miR-335, miR-126 and miR-32, discriminating cancerous and non-malignant tissues. Differences with
p,0.05 were considered statistically significant. *MPM vs. NM.
doi:10.1371/journal.pone.0018232.g002
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of miRNA profiling yet another level of importance.
In this study, the miRNA profile was determined using biopsies
collected from MPM patients before the diagnosis and, therefore,
the enrolled patients did not receive any adjuvant chemotherapy
or radiation therapy that could affect expression of the individual
miRNAs. Also, the qRT-PCR array we used allowed quantifica-
tion of miRNA expression. Using this approach, we identified
eight significantly downregulated miRNAs. Of these, three most
consistently deregulated miRNAs were analyzed in 27 cancerous
and adjacent non-malignant tissue sample pairs, resulting in the
identification of miR-126 as promising markers that may be
potentially utilized to distinguish cancerous and normal tissue.
More specifically, we observed low levels of miR-126 in MPM
samples, with their expression independent of tumour staging (cf
Fig. 2,3).
The expression of miR-126 has been recently found to be low
in human lung cancer cells. More specifically, miR-126 has a
binding site in the 39-untranslated region (39-UTR) of the
VEGF-A mRNA, and its upregulation resulted in decreased
expression of VEGF-A. These results suggest a tumor suppressor
function of miR-126 in the context of lung cancer [39], which is
strongly dependent on the production of angiogenic factors.
VEGF, which is secreted by tumor cells and is essential for
tumour vascularization [40], is predicted to be a target for a
variety of miRNA species [41], including miR-126 [39].
Collectively, miRNAs in cancer cells are likely to contribute to
the regulation of tumor angiogenesis by affecting the paracrine
signalling between cancer cells and endothelial cells of the
vasculature.
One of the major challenges in MM is the identification of
biomarkers for early detection of the disease, which can be
routinely measured in surrogates. Recently, circulating miRNAs
have been shown as promising biomarkers for detection of
human cancers [42]. Here, we estimated the risk of MPM in an
asbestos-exposed population via assessment of serum miR-126 in
relation to asbestos exposure parameters, the angiogenic
mediator VEGF and the tumor marker SMRPs. Multivariate
logistic regression analysis revealed that miR-126 was not affected
by asbestos exposure, whereas it was found strongly associated
with VEGF levels. Low expression of miR-126 was correlated
with high levels of VEGF (data not shown). High VEGF levels
and SMRPs were found in the serum of MPM patients compared
with asbestos-exposed subjects and healthy controls (cf Fig. 4A,
B). As previously reported, SMRP levels can distinguish MPM
patients from both asbestos-exposed subjects and controls with an
estimated cut-off of 1 nM. Thus, the level of SMRPs have been
proposed as a biomarker suitable for the diagnosis of existing
MPM but not to predict the disease [6]. Conversely, miR-126
levels can significantly differentiate the high-risk individuals from
healthy controls and the cancer group (cf Fig. 4C). Using ROC
analysis, we calculated the cut-offs for clinical significance,
resulting in dot plots of the combination of markers that were
used to stratify the studied population. When combined with
SMRPs, miR-126 indicates a better performance for the
discrimination of subjects with high-risk to develop tumors,
suggesting a potential diagnostic indicator for patients in the early
stages of MPM (cf Fig. 4D).
In this study, we have identified miRNAs whose expression
differs in the MPM tissue when compared to the corresponding
healthy tissue. Of the various differentially expressed miRNAs,
miR-126 was found to be significantly downregulated in the
malignant tissue. Further, expression of miR-126 can be easily
evaluated in the serum, and its level in association with a specific
Figure 3. Box plot of miR-335, miR-126 and miR-32 expression
levels according to tumor staging. Distribution of miR-335, miR-
126 and miR-32 expression levels (DCT) in S1, MPMs staged S-Ia, S-Ib, S-II
without lymph nodes and metastases involvement and S2, MPMs
staged S-III, S-IV with lymph nodes and metastases involvement. *S1
vs. S2, p,0.05.
doi:10.1371/journal.pone.0018232.g003
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high risk to develop the disease. The identification of tumor
biomarkers used alone or, in particular, in combination could
greatly facilitate the surveillance procedure for cohorts of subjects
exposed to asbestos, a relatively common phenomenon in different
areas of industrialized countries.
Materials and Methods
Ethics statement
All subjects filled a questionnaire including their informed
consent. The study was carried out according to the Helsinki
Declaration and the samples were processed under approval of the
Figure 4. Box plots showing VEGF, SMRPs and miR-126 serum levels. Distribution of VEGF (A), SMRPs (B), miR-126 (C) levels and SMRPs-miR-
126 association (D) in asbestos-exposed subjects (Exp); MPM patients and healthy controls (Ctrl) are shown. Based on the percentile analysis, a cut-off
for SMRPs was determined to discriminate asbestos-exposed subjects and healthy controls from MPM patients. Two cut-offs were calculated for miR-
126 to discriminate asbestos-exposed subjects from healthy controls (DCT=23.5) and from MPM patients (DCT=24.5) *Ctrl vs. Exp and MPM; Exp vs.
MPM, p,0.05.
doi:10.1371/journal.pone.0018232.g004
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Hospital of Marche, Italy.
Specimens
To obtain biopsy specimens, 22 subjects (aged 69.8610.1 years;
20 males, 2 females) who underwent thoracoscopy or thoracotomy
for suspected MPM were enrolled. The collected tissue was
divided into two parts; one was immediately suspended in the
RNALater solution (Ambion, Austin, TX, USA) and stored at
280uC until RNA extraction. The other tissue portion was used
for histological examination by the Pathological Anatomy Unit of
the Hospital University of Ancona, Italy. According to the
diagnosis, the individuals were classified as subjects with MPM
(the MPM group) and as healthy subjects with normal mesothe-
lium (the NM group). The MPM group included tissue with clear
signs of the pathology (n=10), while the NM group included non-
malignant tissue (n=5). The exclusion criteria were the presence
or suspicion of any infectious disease and other malignancies.
Tumors were classified as epithelioid, sarcomatoid, biphasic, and
the tumor stage evaluated based on the recommendation by the
International Mesothelioma Interest Group (IMIG) [20]. The
demographic and pathological characteristics of the subjects are
summarized in Table 1.
Formalin-fixed, paraffin-embedded (FFPE) tissue of the subjects
affected by MPM (n=27) was collected from the Archive of the
Pathological Anatomy Unit of the Hospital University of Ancona,
Italy. The FFPE samples were cut into 5 mm sections and stored at
room temperature until analysis. The adjacent non-cancerous
tissue was used as a control. The clinical data were obtained
retrospectively and included information on the gender, age,
histology, neoadjuvant chemoradiation and therapy administra-
tion (before surgery), smoking status and the pathologic staging.
The MPM sub-types were as follows: 23 epithelioid, 1 sarcomatoid
and 3 biphasic. The demographic and pathological characteristics
of the subjects are summarized in Table 2. The patients were not
treated with any adjuvant chemotherapy or radiation therapy.
Study population
Asbestos-exposed subjects. From November 2004 to April
2010, 196 subjects (mean age 60.969.6 years, 188 males, 8
females) with a history of asbestos exposure were enrolled at the
Institute of Occupational Medicine, Polytechnic University of
Marche, Ancona, Italy. The participants were interviewed by
trained personnel and answered a detailed questionnaire on
duration of asbestos exposure, smoking and occupational tasks.
Each subject underwent lung function analysis, chest radiography,
and high-resolution computed tomography. A ‘fiber-year’
exposure metric was calculated for each subject, assigning to
each person an arbitrary coefficient of ‘inhalated fibers (ff)’
indicating the occupational hazard. The ‘cumulative fibers’ (Cf)
are interpreted as the cumulative dose of asbestos fibers in the
workplace of (ff/cm
3)6yrs [21]. The subjects had been exposed to
asbestos fibers on average for 23.3610.7 years with a Cf of
28.8650.4 (ff/cm
3)6yrs. Smokers 87/196 (44%), ex-smokers 31/
196 (16%) and non-smokers 78/196 (40%) were examined.
Table 1. Demographic and pathological characteristics of
individual subjects.
Biopsies
Age
(years)
Sex
(M/F)
Smoking
(yes/ex/no)
Histotype
(EP/BI/SA) Stage
MPM-1 68 M ex EP S-Ib
MPM-2 63 M no EP S-Ia
MPM-3 66 M no EP S-Ia
MPM-4 75 M yes EP S-IV
MPM-5 81 F yes EP S-III
MPM-6 70 M ex EP S-Ia
MPM-7 75 M ex EP S-III
MPM-8 66 M no EP S-III
MPM-9 83 M no SA -
MPM-10 77 M no EP -
NM-1 80 F yes - -
NM-2 58 M yes - -
NM-3 83 M no - -
NM-4 60 M no - -
NM-5 61 M no - -
EP, epithelioid; SA, sarcomatoid; S-Ia (any T1a); S-Ib (any T1b); S-II (any T2); S-III
(any T3, any N); S-IV (any T4, any N, any M).
doi:10.1371/journal.pone.0018232.t001
Table 2. Demographic and pathological characteristics of
MPM patients.
FFPE
tissues
Age
(years)
Sex
(M/F)
Smoking
(yes/ex/no)
Histotype
(EP/BI/SA) Stage
MPM-1 70 M no EP S-IV
MPM-2 66 M yes EP S-III
MPM-3 71 M yes EP S-III
MPM-4 66 M ex EP S-III
MPM-5 72 M ex EP S-I
MPM-6 59 M ex EP S-III
MPM-7 62 M no BI S-I
MPM-8 80 M no EP S-II
MPM-9 57 F no SA S-I
MPM-10 78 M ex EP S-III
MPM-11 70 M yes EP S-III
MPM-12 75 M yes EP S-III
MPM-13 75 M no EP S-I
MPM-14 69 F yes EP S-II
MPM-15 74 M ex EP S-II
MPM-16 74 M no EP S-I
MPM-17 68 M no EP S-I
MPM-18 63 M yes EP -
MPM-19 70 F no EP -
MPM-20 45 M no EP -
MPM-21 67 M ex EP S-I
MPM-22 70 M no BI S-I
MPM-23 75 M yes EP S-I
MPM-24 44 M no EP S-I
MPM-25 77 M no EP -
MPM-26 78 M ex BI S-III
MPM-27 73 M ex EP S-I
EP, epithelioid; SA, sarcomatoid; BI, Biphasic; S-I (any T1a, any T1b); S-II (any T2);
S-III (any T3, any N); S-IV (any T4, any N, any M).
doi:10.1371/journal.pone.0018232.t002
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was found in 56/196 (29%) subjects.
MPM patients. 44 patients (mean age 63610; 37 males, 7
females) diagnosed for MPM, were recruited, from November
2004 to January 2010, at the Oncology Clinic of the University
Hospital of Ancona, Italy, and included smokers 18/44 (41%), ex-
smokers 7/44 (16%) and non-smokers 19/44 (43%). Exclusion
criteria were the presence or suspicion of any infectious disease,
previous radical surgery, radiotherapy, as well as chemotherapy
for MPM. Pathological diagnosis was performed on pleural
biopsies obtained by thoracoscopy or thoracotomy. Tumors
were classified as epithelial in 30, mixed in 8 and sarcomatoid in
6 patients, and the tumor stage was evaluated.
Healthy-controls. The control group consisted of 50 healthy
subjects (mean age 6868 years; 40 males, 10 females) recruited
from November 2004 to January 2010, and included smokers 27/
50 (54%), ex-smokers 4/50 (8%) and non-smokers 19/50 (38%).
The subjects were undergoing screening radiography for
chemoprevention at the Pneumology Clinic of the University
Hospital of Ancona, Italy. None of them had ever been
occupationally exposed to asbestos as documented by their
occupational histories, and they presented with normal chest
radiographs. Venous blood was collected from each subject at the
time of clinical examination and serum prepared.
Quantitative RT-PCR analysis
Total RNA was extracted from biopsies using Tri-Reagent
(Sigma, St Louis, MO, USA) according to the manufacturer’s
instructions. MiRNAs were isolated from total RNA by the RT
2
qPCR-grade miRNA isolation kit (SABiosciences, Frederick, MD,
USA), and the cDNA synthesized using the RT
2 miRNA First
Strand kit (SABiosciences) according to the manufacturer’s
instructions. The expression of 88 miRNA species involved in
human cancer development (array MAH-102A, SABiosciences)
was assessed by qRT- PCR (Mastercycler EP Realplex, Eppen-
dorf, Milano, Italy) using RT
2 SYBR Green qPCR Master Mix
(SABiosciences).
Total RNA from the FFPE tissue samples (10 mg) was obtained
using the RecoverAll total nucleic acid isolation kit (Ambion,
Austin, TX, USA) according to the manufacturer’s instructions.
Expression of selected miRNA species was quantified by qRT-
PCR (Mastercycler EP Realplex) using the TaqMan MicroRNA
Assay (Applied Biosystems, Foster City, CA, USA).
Circulating RNA was isolated by adding to 250 ml of serum an
equal volume of Tri-Reagent BD (Sigma, St Louis, MO), the
phase lock gel (Eppendorf) was used to improve RNA recovery.
The miRNA isolation kit (SABiosciences) was used for miRNA
purification. miRNAs were eluted in a final volume of 40 ml
RNase free water and 4 ml were reverse-transcribed to cDNA
using individual TaqMan MicroRNA Assay and the expression
quantified by qRT-PCR.
To normalize the expression levels of target miRNA, the U6
small nuclear RNA was used as a control (housekeeping).
Soluble mesothelin-related peptide (SMRP) assay
The level of SMRPs was assessed using a sandwich-type ELISA
assay (Mesomark, Schering, Milano, Italy) according to the
manufacture’s instructions, and the results are expressed in
nmol/l. Briefly, 100 ml of standard and plasma samples (1:100
dilution) were added to each well of a 96-well microtitre plate
coated with specific antibodies against SMRPs and incubated at
room temperature for 60 min. After washing, the plate was
incubated with a secondary HRP-conjugated antibody. The
detection process included the addition of 100 ml of the TMB
(3,39,5,59-Tetramethylbenzidine) substrate to each well and the
absorbance was read at 405 nm using an ELISA plate reader
(Sunrise, Tecan, Milano, Italy). Concentrations of SMRPs were
extrapolated from the standard curve, and expressed in nM.
Vascular endothelial growth factor (VEGF) assay
Human VEGF ELISA kit (EuroClone, Paignton, UK) was used
according to the manufacturer’s instructions to assess levels of the
cytokine in serum samples. The results are expressed in pg/ml.
Statistical analysis
The results were expressed as mean6S.D. of DCT (CT of
miRNA - CT of housekeeping) and high miRNA DCT value
corresponded to low miRNA expression. The fold changes in
relative miRNA expression were calculated using the equation
2
2D(DCt). MiRNA species that were not detected in any of samples
or with a CT value .35 were excluded from the comparison.
Differences with p,0.05 were considered statistically significant.
The miRNA species with at least a two-fold expression change
between groups were considered differentially expressed. The
cluster analysis was performed on the basis of the DDCT log
values, and the resulting expression map was visualized with
Treeview using the average-linkage clustering algorithms (Eisen
Lab, Stanford University, CA, USA). The miRNA species with
increased expression are indicated by red color, those with
decreased expression are shown in green color. Yellow color
indicates miRNAs whose expression was similar in the MPM and
NM groups. Black color indicates miRNAs that were not detected.
Statistical significance of different expression between two
groups was determined by means of the t-test and paired t-test.
Multiple comparisons were determined by Analysis of Variance
(ANOVA) followed by the Post-hoc LSD test. Correlations were
performed according to Pearson. Receiver operating characteris-
tics (ROC) curves were plotted to quantify the marker perfor-
mance. The area under curve (AUC) indicates the average
sensitivity of a marker over the entire ROC curve. The robustness
of the models was evaluated using bootstrap techniques. The best
statistical cut-offs were calculated by minimizing the distance
between the point with sensitivity=1 and specificity=1 and the
intercept on the ROC curve. Multivariate logistic regression
model was used to estimate the influence of independent variables
such as asbestos-related diseases (fibrosis and pleural plaques),
duration of asbestos exposure, cumulative fibre doses, VEGF and
SMRP levels on the selected miRNA.
The data were analyzed by the Statistical Package Social
Sciences (version 15) software (SPSS, Chicago, IL, USA).
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